PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Financials Pacific Biosciences of California, Inc.
Equities
PACB
US69404D1081
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.47 USD | +6.52% |
|
-5.16% | -85.02% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 786.6 | 4,833 | 4,513 | 1,850 | 2,624 | 400.3 | - | - |
| Enterprise Value (EV) 1 | 753.4 | 4,514 | 4,365 | 1,974 | 2,884 | 832 | 901.9 | 963.3 |
| P/E ratio | -9.35 x | 153 x | -23 x | -5.84 x | -8.11 x | -1.41 x | -1.74 x | -2.35 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 8.65 x | 61.3 x | 34.6 x | 14.4 x | 13.1 x | 2.07 x | 1.41 x | 1.06 x |
| EV / Revenue | 8.29 x | 57.2 x | 33.4 x | 15.4 x | 14.4 x | 4.31 x | 3.17 x | 2.56 x |
| EV / EBITDA | -8.08 x | -46.1 x | -21.5 x | -6.65 x | -9.16 x | -3.13 x | -4.52 x | -6.74 x |
| EV / FCF | -9.28 x | 244 x | -37.3 x | -7.05 x | -10.8 x | -3.63 x | -5.32 x | -10.8 x |
| FCF Yield | -10.8% | 0.41% | -2.68% | -14.2% | -9.29% | -27.6% | -18.8% | -9.24% |
| Price to Book | 14.3 x | 12.8 x | 5.72 x | 3.29 x | 3.75 x | 0.78 x | 0.92 x | 1.13 x |
| Nbr of stocks (in thousands) | 153,034 | 186,309 | 220,598 | 226,109 | 267,444 | 272,280 | - | - |
| Reference price 2 | 5.140 | 25.94 | 20.46 | 8.180 | 9.810 | 1.470 | 1.470 | 1.470 |
| Announcement Date | 2/6/20 | 2/10/21 | 2/15/22 | 2/16/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 90.89 | 78.89 | 130.5 | 128.3 | 200.5 | 193.1 | 284.8 | 376.8 |
| EBITDA 1 | -93.28 | -97.96 | -202.9 | -296.8 | -314.7 | -265.5 | -199.6 | -142.9 |
| EBIT 1 | -100.5 | -104.4 | -210.4 | -307.2 | -334.5 | -286.2 | -228 | -171.5 |
| Operating Margin | -110.62% | -132.31% | -161.24% | -239.43% | -166.8% | -148.22% | -80.08% | -45.5% |
| Earnings before Tax (EBT) 1 | -84.13 | 29.4 | -274.9 | -314.2 | -318.2 | -279 | -234.2 | -178 |
| Net income 1 | -84.13 | 29.4 | -181.2 | -314.2 | -306.7 | -282.6 | -235.3 | -178 |
| Net margin | -92.57% | 37.27% | -138.85% | -244.92% | -152.97% | -146.34% | -82.63% | -47.23% |
| EPS 2 | -0.5500 | 0.1700 | -0.8900 | -1.400 | -1.210 | -1.039 | -0.8440 | -0.6267 |
| Free Cash Flow 1 | -81.15 | 18.46 | -117.1 | -280 | -268 | -229.3 | -169.6 | -88.97 |
| FCF margin | -89.28% | 23.4% | -89.73% | -218.2% | -133.66% | -118.76% | -59.54% | -23.61% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | 62.8% | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/6/20 | 2/10/21 | 2/15/22 | 2/16/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 34.89 | 36.02 | 33.17 | 35.47 | 32.31 | 27.35 | 38.9 | 47.57 | 55.69 | 58.36 | 42.58 | 45.86 | 50.14 | 56.59 | 59.58 |
| EBITDA 1 | -72.58 | -62.19 | -75.03 | -65.42 | -72.04 | -84.31 | -88.26 | -71.12 | -68.2 | -77.72 | -73.4 | -69.26 | -65.48 | -62.68 | -63 |
| EBIT 1 | -74.48 | -64.68 | -77.52 | -67.97 | -74.62 | -87.08 | -91.25 | -73.18 | -73.04 | -87.55 | -76.64 | -72.68 | -69.98 | -67.45 | -67.06 |
| Operating Margin | -213.48% | -179.56% | -233.69% | -191.64% | -230.94% | -318.37% | -234.58% | -153.82% | -131.16% | -150.02% | -179.98% | -158.49% | -139.59% | -119.19% | -112.55% |
| Earnings before Tax (EBT) 1 | -78.28 | -68.15 | -81.5 | -71.39 | -76.97 | -84.38 | -88.02 | -69.83 | -77.58 | -82.74 | -76.42 | -72.51 | -69 | -66.2 | -66.32 |
| Net income 1 | 16.54 | -69.33 | -81.5 | -71.39 | -76.97 | -84.38 | -88.02 | -69.83 | -66.87 | -82.02 | -76.42 | -72.51 | -69 | -66.2 | -66.32 |
| Net margin | 47.42% | -192.48% | -245.68% | -201.3% | -238.22% | -308.5% | -226.26% | -146.79% | -120.07% | -140.55% | -179.47% | -158.11% | -137.63% | -116.98% | -111.32% |
| EPS 2 | 0.0800 | -0.3100 | -0.3700 | -0.3200 | -0.3400 | -0.3700 | -0.3600 | -0.2800 | -0.2600 | -0.3100 | -0.2811 | -0.2644 | -0.2511 | -0.2411 | -0.2380 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/2/21 | 2/15/22 | 5/4/22 | 8/3/22 | 11/7/22 | 2/16/23 | 5/2/23 | 8/2/23 | 10/30/23 | 2/15/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 124 | 261 | 432 | 502 | 563 |
| Net Cash position 1 | 33.2 | 319 | 148 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | -0.419 x | -0.8287 x | -1.626 x | -2.513 x | -3.941 x |
| Free Cash Flow 1 | -81.1 | 18.5 | -117 | -280 | -268 | -229 | -170 | -89 |
| ROE (net income / shareholders' equity) | -99.6% | 7.53% | -33.7% | -46.4% | -48.5% | -42.4% | -46.1% | -32.7% |
| ROA (Net income/ Total Assets) | -52.9% | 5.23% | -15.7% | -16.5% | -17.5% | -14.7% | -14.3% | - |
| Assets 1 | 159.1 | 562 | 1,154 | 1,907 | 1,757 | 1,919 | 1,643 | - |
| Book Value Per Share 2 | 0.3600 | 2.030 | 3.580 | 2.490 | 2.620 | 1.890 | 1.590 | 1.300 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 2.84 | 1.04 | 5.93 | 16.8 | 8.84 | 9.17 | 11.9 | 13.9 |
| Capex / Sales | 3.12% | 1.32% | 4.54% | 13.05% | 4.41% | 4.75% | 4.19% | 3.69% |
| Announcement Date | 2/6/20 | 2/10/21 | 2/15/22 | 2/16/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
1.47
USD
Average target price
5.818
USD
Spread / Average Target
+295.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -85.02% | 400M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B | |
| +26.76% | 32.03B |
- Stock Market
- Equities
- PACB Stock
- Financials Pacific Biosciences of California, Inc.
